cAMPfield Therapeutics, Inc., a clinical-stage biopharmaceutical company formed to develop well-tolerated and highly effective oral medicines for immune-mediated inflammatory diseases, has launched with a US$180 million Series A financing to advance prifemilast (HY1999/HPP737), a once-daily oral PDE4 inhibitor, for the treatment of inflammatory bowel disease (IBD). The Series A financing was supported by top tier investors led by Frazier Life Sciences, and included Deep Track Capital, Forbion, Abingworth, Venrock, Longitude Capital, Novo Holdings, and RA Capital.
Latham & Watkins LLP advised cAMPfield in the transaction with a corporate team led by San Diego partners Matt Bush and Christian Hollweg, with associate Alex Stuart-Lovell. Advice was also provided on licensing matters by San Diego counsel Robert Yeh.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
